论文部分内容阅读
雷尼酸锶是一种具有双重功效的抗骨质疏松制剂,它可以促进骨形成,抑制其重吸收,并且通过促进骨形成来增加骨强度,从而使骨交换达到平衡。通过在世界范围内收集7000多病例,在研究的3个阶段中,所有病例口服雷尼酸锶2 g/d,研究雷尼酸锶的抗骨质作用。现就雷尼酸锶治疗绝经期妇女因骨质疏松而导致的脊椎骨折的效果进行介评。雷尼酸锶有明显的早期(1年后)和持续(3年后)抗骨折功效,在高危人群中1年和3年的新发脊椎骨折危险度分别下降49%和41%。除此之外,1年和3年临床发生脊椎骨折的相对危险度(RR)也分别明显下降52%和38%。在非高危人群中雷尼酸锶也能将脊椎骨折相对危险度下降45%,在3年的雷尼酸锶治疗中骨矿物质密度呈线性增长。因此,口服2 g/d雷尼酸锶对治疗有或没有脊椎骨折史的绝经期妇女的骨质疏松症是一种崭新、有效、安全的方法。
Strontium ranelate is a dual-effect anti-osteoporosis preparation that promotes bone formation, inhibits its reabsorption, and increases bone strength by promoting bone formation to balance bone exchange. Through the worldwide collection of more than 7,000 cases, strontium ranelate was studied for its anti-osteogenic effects by oral administration of 2 g / d of strontium ranelate in all three stages of the study. Is the strontium ranelate treatment of menopausal women due to osteoporosis caused by the effect of vertebral fracture were evaluated. Strontium ranelate had marked early (1 year) and sustained (3 years) anti-fracture efficacy, and the risk of new-onset vertebral fractures at 1 year and 3 years decreased by 49% and 41%, respectively, in high-risk groups. In addition, the relative risk (RR) for vertebral fractures at 1 year and 3 years decreased significantly by 52% and 38%, respectively. Strontium ranelate also reduced the relative risk of vertebral fractures by 45% in non-at-risk populations, with a linear increase in bone mineral density over the three years of treatment with strontium ranelate. Therefore, oral administration of 2 g / d of strontium ranelate is a novel, effective and safe method of treating osteoporosis in postmenopausal women with or without a history of spinal fractures.